Study of Focal Mass Drug Administration to Prevent Plasmodium vivax Malaria in Loreto, Peru
A Randomized Trial Comparing Standard Care to Targeted Drug Treatment
Led by University of California, San Francisco · Updated on 2026-06-09
7530
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness of focal mass drug administration fMDA in reducing the incidence of Plasmodium vivax malaria in the Loreto Department of Peru. This open-label cluster-randomized controlled trial compares standard malaria control interventions with additional targeted drug administration in high-risk village clusters. The study aims to assess the impact of fMDA on malaria transmission, safety, and cost-effectiveness over a three-year period in a low transmission setting.
Participants live in villages randomized to either standard malaria control measures or fMDA. Standard interventions include insecticide-treated bednets, management of mosquito breeding sites, symptomatic case detection, and treatment. The fMDA group receives two rounds of targeted antimalarial drugs per cycle, repeated for three cycles. Drugs used include chloroquine, tafenoquine, and primaquine, with dosing based on age and G6PD status. High-risk individuals are those living within 200 meters of confirmed malaria cases in the past two years. Testing and counseling for G6PD deficiency are done before drug administration.
Participants are monitored through baseline and endline surveys collecting dried blood spots and fever screening with treatment per national guidelines. Safety is evaluated by tracking severe adverse events and malaria cases. Cost-effectiveness and acceptability of the intervention are also measured. The primary outcome is the cumulative incidence of P. vivax infection over 36 months. The trial is conducted pragmatically through the existing health system with follow-up extending over four years.
CONDITIONS
Brief Title
FocaL Mass Drug Administration for Vivax Malaria Elimination
Research Team
S
Sydney Fine, MPH
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Village had malaria incidence between 2 and 250 cases per 1000 in the year before trial
Village population is fewer than 650 people
Resides in household within 200 meters of Plasmodium vivax index case in past 2 years
Age 6 months or older
Present in village during intervention
Adults aged 18 years or older provide informed consent
Children aged 8 to less than 18 years provide assent and have parental consent
Children aged 6 months to less than 8 years have parental consent
Villagers slept in cluster household at least one night in past 4 weeks
High-risk villagers are eligible for fMDA within each cycle
You will not qualify if you...
History of retinal or visual field changes
Known allergy or adverse reaction to chloroquine
Took chloroquine or other antimalarial in past 4 weeks
Hemoglobin level less than 9 g/dL
G6PD deficiency or intermediate status (based on biosensor test)
Unknown or refused G6PD test
Acute or severe malaria
Pregnancy or refusal of pregnancy test if recent missed menstruation
Breastfeeding a child with unknown or deficient G6PD status
Known allergy or adverse reaction to tafenoquine or primaquine
Took mefloquine, tafenoquine, primaquine, or other antimalarials in past 4 weeks
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Intervention
Duration - 3 years
Participants in villages receive either standard malaria control measures or targeted focal mass drug administration with antimalarial drugs given in two rounds per cycle for three cycles. Drug dosing depends on age and G6PD status.
Follow-up and Surveys
Duration - Up to 4 years
Surveys are conducted to collect blood samples and monitor malaria infections. Participants with fever are tested and treated per national guidelines. Safety and cost-effectiveness are also evaluated.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Phase 2a Study of RTS,SAS01E Malaria Vaccine Doses and Schedules in Healthy Children Aged 5 to 60 Months in a Malaria Area
Comparing High-Dose Tafenoquine Combined With Artemisinin or Chloroquine Treatments for Plasmodium Vivax Malaria
Assessing the Effectiveness of the R21Matrix-M Malaria Vaccine in Children Under 5 in Burkina Faso and Uganda
Collection of Human Biospecimens for Research on Globin Variants in Blood Disorders Including Sickle Cell Disease and Malaria
Study of Malaria Vaccine Impact on Invasive Non-Typhoidal Salmonella Disease Risk in Children Under 5 in Kisantu Health Zone
Study of Artesunate Drug Levels in Infants Treated for Severe Malaria Under 2 Years Old
Evaluation, Treatment, and Monitoring of Patients with Known or Suspected Parasitic Infection Using Standard Medical Practices
Study of Focal Mass Drug Administration to Prevent Plasmodium vivax Malaria in Loreto, Peru
A Randomized Trial Comparing Standard Care to Targeted Drug Treatment
Studying Factors That Affect Malaria Infection and Disease in Pregnant Women and Young Children in Mali
Phase 1 Study to Assess Safety, Infectivity, and Transmission of Plasmodium Vivax Malaria in Healthy Adults
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
FocaL mass drug Administration for Plasmodium vivax Malaria Elimination (FLAME): study protocol for an open-label cluster randomized controlled trial in Peru.
Sydney Fine, Astrid Altamirano Quiroz, Veronica Soto Calle...
Effectiveness of reactive focal mass drug administration and reactive focal vector control to reduce malaria transmission in the low malaria-endemic setting of Namibia: a cluster-randomised controlled, open-label, two-by-two factorial design trial.
Michelle S Hsiang, Henry Ntuku, Kathryn W Roberts...
FocaL mass drug administration for Plasmodium vivax malaria elimination (FLAME): study protocol for an open-label cluster randomized controlled trial in Peru.
Sydney R Fine, Veronica Soto Calle, Astrid Altamirano Quiroz...
Cost and cost effectiveness of reactive case detection (RACD), reactive focal mass drug administration (rfMDA) and reactive focal vector control (RAVC) to reduce malaria in the low endemic setting of Namibia: an analysis alongside a 2×2 factorial design cluster randomised controlled trial.